Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
Amgen revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Amgen's revenue for the twelve months ending Sep 30, 2026 was $38.90B, up 8.2% year over year. For fiscal 2025 it was $36.75B, up 10.0% from the year before. Over ten years it grew 5.4% a year on average. The highest annual figure on record is $36.75B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.75B | +10.0% |
| FY2024 | Dec 31, 2024 | $33.42B | +18.6% |
| FY2023 | Dec 31, 2023 | $28.19B | +7.1% |
| FY2022 | Dec 31, 2022 | $26.32B | +1.3% |
| FY2021 | Dec 31, 2021 | $25.98B | +2.2% |
| FY2020 | Dec 31, 2020 | $25.42B | +8.8% |
| FY2019 | Dec 31, 2019 | $23.36B | -1.6% |
| FY2018 | Dec 31, 2018 | $23.75B | +3.9% |
| FY2017 | Dec 31, 2017 | $22.85B | -0.6% |
| FY2016 | Dec 31, 2016 | $22.99B | +6.1% |
| FY2015 | Dec 31, 2015 | $21.66B | +8.0% |
| FY2014 | Dec 31, 2014 | $20.06B | +7.4% |
| FY2013 | Dec 31, 2013 | $18.68B | +8.2% |
| FY2012 | Dec 31, 2012 | $17.27B | +10.8% |
| FY2011 | Dec 31, 2011 | $15.58B | +3.5% |
| FY2010 | Dec 31, 2010 | $15.05B | +2.8% |
| FY2009 | Dec 31, 2009 | $14.64B | -2.4% |
| FY2008 | Dec 31, 2008 | $15.00B | +1.6% |
| FY2007 | Dec 31, 2007 | $14.77B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.37B | +8.5% |
| Q2 FY2026 | Jun 30, 2026 | $10.05B | +9.5% |
| Q1 FY2026 | Mar 31, 2026 | $8.62B | +5.8% |
| Q4 FY2025 | Dec 31, 2025 | $9.87B | +8.6% |
| Q3 FY2025 | Sep 30, 2025 | $9.56B | +12.4% |
| Q2 FY2025 | Jun 30, 2025 | $9.18B | +9.4% |
| Q1 FY2025 | Mar 31, 2025 | $8.15B | +9.4% |
| Q4 FY2024 | Dec 31, 2024 | $9.09B | +10.9% |
| Q3 FY2024 | Sep 30, 2024 | $8.50B | +23.2% |
| Q2 FY2024 | Jun 30, 2024 | $8.39B | +20.1% |
| Q1 FY2024 | Mar 31, 2024 | $7.45B | +22.0% |
| Q4 FY2023 | Dec 31, 2023 | $8.20B | +19.8% |
| Q3 FY2023 | Sep 30, 2023 | $6.90B | +3.8% |
| Q2 FY2023 | Jun 30, 2023 | $6.99B | +5.9% |
| Q1 FY2023 | Mar 31, 2023 | $6.11B | -2.1% |
| Q4 FY2022 | Dec 31, 2022 | $6.84B | -0.1% |
| Q3 FY2022 | Sep 30, 2022 | $6.65B | +12.7% |
| Q2 FY2022 | Jun 30, 2022 | $6.59B | -0.6% |
| Q1 FY2022 | Mar 31, 2022 | $6.24B | -2.9% |
| Q4 FY2021 | Dec 31, 2021 | $6.85B | +10.3% |
| Q1 FY2021 | Mar 31, 2021 | $5.90B | -4.2% |
| Q4 FY2020 | Dec 31, 2020 | $6.63B | +13.0% |
| Q3 FY2020 | Sep 30, 2020 | $6.42B | +15.6% |
| Q2 FY2020 | Jun 30, 2020 | $6.21B | -0.4% |
| Q1 FY2020 | Mar 31, 2020 | $6.16B | +4.4% |
| Q2 FY2019 | Jun 30, 2019 | $5.87B | -3.1% |
| Q1 FY2019 | Mar 31, 2019 | $5.56B | +0.1% |
| Q4 FY2018 | Dec 31, 2018 | $6.23B | +11.9% |
| Q3 FY2018 | Sep 30, 2018 | $5.90B | +2.3% |
| Q2 FY2018 | Jun 30, 2018 | $6.06B | +4.3% |
| Q1 FY2018 | Mar 31, 2018 | $5.55B | +1.6% |
| Q4 FY2017 | Dec 31, 2017 | $5.57B | -1.7% |
| Q3 FY2017 | Sep 30, 2017 | $5.77B | +4.7% |
| Q2 FY2017 | Jun 30, 2017 | $5.81B | +6.1% |
| Q1 FY2017 | Mar 31, 2017 | $5.46B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.66B | – |
| Q3 FY2016 | Sep 30, 2016 | $5.52B | – |
| Q2 FY2016 | Jun 30, 2016 | $5.47B | – |
See a number that looks wrong?